Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Ronald Steis

Hematology | Oncology
NSH Cancer Institute Professional Services A LLC
3400 Old Milton Pkwy Ste 400, 
Alpharetta, GA 

Distinguished in WT1-Related Wilms Tumor Syndromes
NSH Cancer Institute Professional Services A LLC
3400 Old Milton Pkwy Ste 400, 
Alpharetta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ronald Steis is a Hematologist and an Oncologist in Alpharetta, Georgia. Dr. Steis is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Thymic Epithelial Tumor, and Paget Disease of the Breast.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in GA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO

Locations

NSH Cancer Institute Professional Services A LLC
3400 Old Milton Pkwy Ste 400, Alpharetta, GA 30005
Call: 770-740-9664

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


3 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine
Study Phase: Phase 2
View 2 Less Clinical Trials

2 Total Publications

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.
Journal: Breast cancer research and treatment
Published: March 20, 2018
View All 2 Publications
Similar Doctors
Vasileios J. Assikis
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Vasileios J. Assikis
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Vasileios J. Assikis
Oncology | Hematology

Piedmont Cancer Institute, PC

1267 Highway 54 West, Suite 4200, 
Fayetteville, GA 
 (54.1 miles away)
678-829-1060
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vasileios Assikis is a Hematologist and an Oncologist in Fayetteville, Georgia. Dr. Assikis is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Adult Soft Tissue Sarcoma, and Renal Cell Carcinoma (RCC). Dr. Assikis is currently accepting new patients.

Stephen M. Szabo
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Stephen M. Szabo
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Stephen M. Szabo
Hematology | Oncology

Piedmont Oncology At Rockdale

1412 Milstead Ave NE, Ste 300, 
Conyers, GA 
 (36.6 miles away)
770-918-2320
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Szabo is board certified in hematology, medical oncology, and internal medicine. He completed his hematology-oncology training at Emory University Hospital and his internal medicine residency at the University of Michigan Hospitals. He earned his medical degree at Cornell University Medical College.Dr. Szabo has been practicing medicine for more than 20 years. Most recently, he was Chief of Staff at Emory St. Joseph Hospital. Prior to that, he was Chief of Staff at Emory Johns Creek Hospital and the Director of the Division of Community Oncology for the Department of Hematology Oncology at Emory Healthcare.Dr. Szabo has special interests in breast cancer, gastrointestinal cancer, and benign and malignant hematology. In his free time, Dr. Szabo enjoys promoting health education, hiking, sailing, and spending time with his family.Dr. Szabo and the team at Piedmont Oncology have the resources you need conveniently close to home.Dr. Szabo is accepting new patients and welcomes most major insurance plans. Dr. Szabo is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Hereditary Neuroblastoma, Inflammatory Breast Cancer, Gastric Lymphoma, Bone Marrow Aspiration, and Colonoscopy.

Bradley C. Carthon
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Bradley C. Carthon
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Bradley C. Carthon
Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (31.2 miles away)
404-778-1900
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bradley Carthon is an Oncologist in Atlanta, Georgia. Dr. Carthon has been practicing medicine for over 21 years and is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Prostatectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Steis's expertise for a condition
ConditionClose
    • Distinguished
    • Adult Soft Tissue Sarcoma
      Dr. Steis is
      Distinguished
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Anal Cancer
      Dr. Steis is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Astrocytoma
      Dr. Steis is
      Distinguished
      . Learn about Astrocytoma.
      See more Astrocytoma experts
    • Atypical Teratoid Rhabdoid Tumor (ATRT)
      Dr. Steis is
      Distinguished
      . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
      See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
    • B-Cell Lymphoma
      Dr. Steis is
      Distinguished
      . Learn about B-Cell Lymphoma.
      See more B-Cell Lymphoma experts
    • Clear Cell Sarcoma
      Dr. Steis is
      Distinguished
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    View All 17 Distinguished Conditions
    • Advanced
    • Acute Hepatic Porphyria (AHP)
      Dr. Steis is
      Advanced
      . Learn about Acute Hepatic Porphyria (AHP).
      See more Acute Hepatic Porphyria (AHP) experts
    • Anemia
      Dr. Steis is
      Advanced
      . Learn about Anemia.
      See more Anemia experts
    • Brain Tumor
      Dr. Steis is
      Advanced
      . Learn about Brain Tumor.
      See more Brain Tumor experts
    • Breast Cancer
      Dr. Steis is
      Advanced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Childhood Iron Deficiency Anemia
      Dr. Steis is
      Advanced
      . Learn about Childhood Iron Deficiency Anemia.
      See more Childhood Iron Deficiency Anemia experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Steis is
      Advanced
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    View All 40 Advanced Conditions
    • Experienced
    • Acute Eosinophilic Pneumonia
      Dr. Steis is
      Experienced
      . Learn about Acute Eosinophilic Pneumonia.
      See more Acute Eosinophilic Pneumonia experts
    • Acute Mountain Sickness
      Dr. Steis is
      Experienced
      . Learn about Acute Mountain Sickness.
      See more Acute Mountain Sickness experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Steis is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Steis is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Steis is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Adrenocortical Carcinoma
      Dr. Steis is
      Experienced
      . Learn about Adrenocortical Carcinoma.
      See more Adrenocortical Carcinoma experts
    View All 106 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved